Clinical implications of disappearing colorectal liver metastases have changed in the era of hepatocyte-specific MRI and contrast-enhanced intraoperative ultrasonography

HPB (Oxford). 2018 Aug;20(8):708-714. doi: 10.1016/j.hpb.2018.02.377. Epub 2018 Mar 10.

Abstract

Background: Clinical implication of disappearing liver metastases (DLMs) from colorectal cancer after chemotherapy needs to be reviewed in the era of modern imaging studies.

Methods: Between 2010 and 2015, 184 patients underwent curative hepatectomy for colorectal liver metastases following preoperative chemotherapy. The sites of metastases detected on pre-chemotherapy CE-CT were examined post-chemotherapy using CE-CT, gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging (EOB-MRI), and contrast-enhanced intraoperative ultrasonography (CE-IOUS). DLMs were defined as tumors that disappeared on CE-CT post chemotherapy. The detection rate of DLMs with EOB-MRI and CE-IOUS were assessed, and the outcome of DLMs resected and those left in place were reviewed.

Results: A total of 275 DLMs were noted in 59 patients. On EOB-MRI, 71 lesions (26%) were visible and were resected, 92% (65/71) of which contained viable disease. Using CE-IOUS, an additional 94 lesions were identified. A total of 165 DLMs (60%) were identified and resected by sequential use of EOB-MRI and CE-IOUS, 77% (127/165) of which contained viable disease. Of 110 DLMs not identified, 68 were resected, 4% (3/68) of which contained viable disease. Among 42 lesions left in place, 6 (14%) recurred during the median follow-up period of 27 (9-72) months.

Discussion: EOB-MRI and CE-IOUS exploration identified clinically relevant DLMs containing viable disease with a high level of accuracy.

Publication types

  • Comparative Study

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Cell Survival
  • Chemotherapy, Adjuvant
  • Clinical Decision-Making
  • Colorectal Neoplasms / pathology*
  • Contrast Media / administration & dosage
  • Female
  • Fluorocarbons / administration & dosage
  • Gadolinium DTPA / administration & dosage
  • Hepatectomy* / adverse effects
  • Humans
  • Intraoperative Care
  • Liver Neoplasms / diagnostic imaging*
  • Liver Neoplasms / secondary
  • Liver Neoplasms / therapy*
  • Magnetic Resonance Imaging*
  • Male
  • Middle Aged
  • Neoadjuvant Therapy* / adverse effects
  • Predictive Value of Tests
  • Reproducibility of Results
  • Treatment Outcome
  • Ultrasonography / methods*

Substances

  • Contrast Media
  • Fluorocarbons
  • gadolinium ethoxybenzyl DTPA
  • Gadolinium DTPA
  • perfluorobutane